ArticleChirurgie (Heidelberg, Germany)2025

[Is the adjuvant administration of imatinib more meaningful over 3 or 6 years in patients with high-risk for recurrent GIST?]

Melissa Harbrücker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.